Anticancer ( rituximab ), monoclonal antibody

1. Rituximab
By Mennatallah Abdelshaheed

2. Rituximab (MabThera™) is a mAb licensed for
use in drug-resistant advanced follicular
lymphoma and for diffuse large B-cell non-
Hodgkin’s lymphoma in combination with other
anticancer drugs.
Rituximab

3. • Antineoplastic Agent, Anti-
CD20
• Antineoplastic Agent,
Monoclonal Antibody
• Antirheumatic Miscellaneous
• Immunosuppressant Agent
• Monoclonal Antibody
Classified as :

4. Rituximab is a monoclonal antibody that targets
the CD20 antigen, which is expressed on the
surface of
pre-B and mature B-lymphocytes.
After binding to CD20, rituximab mediates B-cell
lysis (or breakdown).
The possible mechanisms of cell lysis include
complement dependent cytotoxicity (CDC) and
antibody dependent cell-mediated
cytotoxicity(ADCC).

5. Sequence of events leading to the depletion of
circulating B-Lymphocytes by complement-
dependent cell lysis, antibody-dependentcellular
cytotoxicity, as well as apoptosis .

6. Rituximab belongs to the immunoglobulin
G1 (IgG1) sub-class, consisting of a murine
variable region (Fab region) and a human
constant region (Fc region).

8. Dosage Forms
Solution, Intravenous [preservative free]:
Rituxan: 10 mg/mL (10 mL, 50 mL)

10. Side effects !!

16. US FDA pregnancy category C:
Animal reproduction studies
have shown an adverse effect
on the fetus and there are no adequate
and well-controlled studies in humans, but potential benefits may
warrant use of the drug in pregnant women despite potential risks.
This drug should be used during pregnancy only if the benefit outweighs
the risk.
AU TGA pregnancy category: C
US FDA pregnancy category: C
Rituximab Pregnancy Warnings